![](/images/graphics-bg.png)
A Remarkable Remission: Treating HMA Refractory Transforming MDS with Single-Agent Low-Dose Cytarabine Leading to an Ongoing Six-Year OS
Joint Authors
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-02-14
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Hypomethylating agents (HMA) are the standard of care for patients ≥65 years with intermediate-high risk myelodysplastic syndrome (MDS) unsuitable for intensive therapy or stem cell transplant (SCT).
However, many patients will develop relapse/refractory disease, at which point limited treatment options remain.
There has been a lot of research into investigational agents following HMA failure, especially now into targeted therapy, but there is no final consensus or convincing data to guide clinicians.
Low-dose cytarabine (LDAC) has been in the armamentarium for some time, but the value of LDAC is judged differently by various guidelines.
Nevertheless, in a subgroup of patients who fail on a HMA and wish to continue treatment, LDAC may still have the potential to improve overall survival (OS).
In this case report, we present an 85-year-old gentleman with HMA refractory high-risk/transforming MDS (with a noncomplex karyotype) achieving an ongoing six-year OS with single-agent second-line LDAC.
LDAC may therefore still be considered by clinicians as a therapeutic option, but when available, patients should be enrolled on a clinical trial.
American Psychological Association (APA)
Palmer, David& Jones, Lydia. 2020. A Remarkable Remission: Treating HMA Refractory Transforming MDS with Single-Agent Low-Dose Cytarabine Leading to an Ongoing Six-Year OS. Case Reports in Medicine،Vol. 2020, no. 2020, pp.1-3.
https://search.emarefa.net/detail/BIM-1148376
Modern Language Association (MLA)
Palmer, David& Jones, Lydia. A Remarkable Remission: Treating HMA Refractory Transforming MDS with Single-Agent Low-Dose Cytarabine Leading to an Ongoing Six-Year OS. Case Reports in Medicine No. 2020 (2020), pp.1-3.
https://search.emarefa.net/detail/BIM-1148376
American Medical Association (AMA)
Palmer, David& Jones, Lydia. A Remarkable Remission: Treating HMA Refractory Transforming MDS with Single-Agent Low-Dose Cytarabine Leading to an Ongoing Six-Year OS. Case Reports in Medicine. 2020. Vol. 2020, no. 2020, pp.1-3.
https://search.emarefa.net/detail/BIM-1148376
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1148376